NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS), a leading biotechnology company developing novel Listeria-based therapeutic cancer vaccines today announced it has closed a $9.4 million equity private placement. The company raised gross proceeds of $9.4 million through the sale of common stock and warrants to several institutional and accredited investors.
